News

Public · Published

HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan

HUTCHMED said European and Japanese regulators accepted filings for review of ORPATHYS® (savolitinib) combined with TAGRISSO® (osimertinib) for certain patients with MET-driven, EGFR-mutated non-small cell lung cancer. The European application was submitted by AstraZeneca; AstraZeneca also submitted the Japanese application.

Published:

Updated:

What happened

HUTCHMED said European and Japanese regulators accepted filings for review of ORPATHYS® (savolitinib) combined with TAGRISSO® (osimertinib) for certain patients with MET-driven, EGFR-mutated non-small cell lung cancer. The European application was submitted by AstraZeneca; AstraZeneca also submitted the Japanese application.

Confirmed

Global impact / market context

Acceptance starts regulatory review but does not mean either region has approved the treatment. If approvals follow, the combination could become available to eligible patients in Europe and Japan, creating a potential commercial opportunity for HUTCHMED and its partner AstraZeneca; sales impact is not yet established.

Analyst inference

The filings follow a US drug application submission in September 2026, according to the article, extending the regulatory effort across three regions. The article says the applications are supported by positive Phase III trial results, but gives no sales forecasts, approval timetable, or financial terms.

Confirmed

What to watch

  1. Watch for the European Medicines Agency and Japan’s health ministry to complete their reviews and announce decisions; acceptance for review is not an approval. Analyst inference
  2. The article says the filings rely on SAFFRON Phase III results showing significant improvements in progression-free and overall survival; review outcomes will determine whether regulators accept that evidence. Confirmed
  3. Any eventual approval could broaden the treatment’s reach, but commercial effects depend on eligible patient numbers, launch timing, and terms between HUTCHMED and AstraZeneca, none of which are supplied. Analyst inference

Evidence